Question 1

Which of the following is not a potential side effect/risk with exogenous testosterone therapy?

Accepted Answer

A)  Elevated liver enzymes 
B)  Hyperlipidemia 
C)  Diabetes 
D)  Peptic ulcer disease 
A)  Elevated liver enzymes 
B)  Hyperlipidemia 
C)  Diabetes 
D)  Peptic ulcer disease D

Question 2

Among trans women, the risk for deep venous thrombosis is higher if:

Accepted Answer

A)  They use oral estrogen replacement 
B)  They use cutaneous estrogen replacement 
C)  They take spironolactone 
D)  They use goserelin as a GnRH agonist 
A)  They use oral estrogen replacement 
B)  They use cutaneous estrogen replacement 
C)  They take spironolactone 
D)  They use goserelin as a GnRH agonist A

Question 3

Which of the following is true of trans men?

Accepted Answer

A)  Contraception is no longer needed. 
B)  A quarterly lab to monitor hormonal treatment is recommended for life. 
C)  There is an increased risk of polycystic ovarian syndrome. 
D)  There is an increased risk of migraine headaches. 
A)  Contraception is no longer needed. 
B)  A quarterly lab to monitor hormonal treatment is recommended for life. 
C)  There is an increased risk of polycystic ovarian syndrome. 
D)  There is an increased risk of migraine headaches. C

Question 4

Every effort should be made to treat other medical conditions prior to beginning gender-affirming treatments. Which of the following would be imperative to address/treat prior to beginning treatments?

Accepted Answer

A)  Cardiovascular disease 
B)  Depression/mood disorders 
C)  Urological conditions 
D)  Sleep disturbances 
A)  Cardiovascular disease 
B)  Depression/mood disorders 
C)  Urological conditions 
D)  Sleep disturbances

Question 5

Which of the following is true concerning gender-affirming treatments?

Accepted Answer

A)  All transgender patients elect gender-affirming treatments. 
B)  Trans males are more likely to use pharmacological treatments over nonpharmacological treatments. 
C)  Gender-affirming treatments are reserved for those preparing for transition surgery. 
D)  Not all individuals undergo gender-affirming treatments. 
A)  All transgender patients elect gender-affirming treatments. 
B)  Trans males are more likely to use pharmacological treatments over nonpharmacological treatments. 
C)  Gender-affirming treatments are reserved for those preparing for transition surgery. 
D)  Not all individuals undergo gender-affirming treatments.

Question 6

For trans men on hormone therapy, labs to assess treatment response should include a complete blood count (CBC). For what, specifically, is it important to monitor the CBC?

Accepted Answer

A)  Anemia 
B)  Thrombocytopenia 
C)  Polycythemia 
D)  Neutropenia 
A)  Anemia 
B)  Thrombocytopenia 
C)  Polycythemia 
D)  Neutropenia

Question 7

Your transgender patient has had a gonadectomy and is no longer on hormone replacement. You should screen for:

Accepted Answer

A)  Free testosterone 
B)  Deep venous thrombosis 
C)  Bone density 
D)  All of the above 
A)  Free testosterone 
B)  Deep venous thrombosis 
C)  Bone density 
D)  All of the above

Question 8

Hormonal therapies for trans women carry increased risks for:

Accepted Answer

A)  Electrolyte abnormalities 
B)  Weight gain 
C)  Deep vein thrombosis 
D)  All of the above 
A)  Electrolyte abnormalities 
B)  Weight gain 
C)  Deep vein thrombosis 
D)  All of the above

Question 9

For both trans women and trans men receiving gender-affirming treatments, labs should be monitored at regular intervals. The recommendation for follow-up intervals is:

Accepted Answer

A)  Every 3 months for the first year, then once or twice annually 
B)  Every month for the first year, then every 3 months after that 
C)  Every 6 months for the first year, then annually 
D)  Regular labs should be checked annually 
A)  Every 3 months for the first year, then once or twice annually 
B)  Every month for the first year, then every 3 months after that 
C)  Every 6 months for the first year, then annually 
D)  Regular labs should be checked annually

Question 10

Contraindications for testosterone therapy in trans men include:

Accepted Answer

A)  Anemia 
B)  Pregnancy 
C)  Gallbladder disease 
D)  History of deep venous thrombosis 
A)  Anemia 
B)  Pregnancy 
C)  Gallbladder disease 
D)  History of deep venous thrombosis

Question 11

Gender-neutral pronouns are often used to avoid assuming the binary gender classifications denoted by pronouns such as he and she. Which of the following is not a gender-neutral pronoun?

Accepted Answer

A)  Ze 
B)  Hir 
C)  They 
D)  Person 
A)  Ze 
B)  Hir 
C)  They 
D)  Person

Question 12

While seeing a trans-male patient with an acute complaint, you should not:

Accepted Answer

A)  Obtain demographic information, including what the patient chooses to be called 
B)  Complete a focused medical history specific to the complaint 
C)  Document all prior gender reassignment procedures 
D)  Document all current medications 
A)  Obtain demographic information, including what the patient chooses to be called 
B)  Complete a focused medical history specific to the complaint 
C)  Document all prior gender reassignment procedures 
D)  Document all current medications

Question 13

The term transgender is used to describe all of the following except:

Accepted Answer

A)  Individuals whose gender identity varies from the gender assigned at birth 
B)  Individuals who fluidly identify as neither male nor female 
C)  Individuals classified by sexual orientation 
D)  Approximately 1 million individuals in the United States 
A)  Individuals whose gender identity varies from the gender assigned at birth 
B)  Individuals who fluidly identify as neither male nor female 
C)  Individuals classified by sexual orientation 
D)  Approximately 1 million individuals in the United States

Which of the following is not a potential side effect/risk with exogenous testosterone therapy?

Among trans women, the risk for deep venous thrombosis is higher if:

Which of the following is true of trans men?

Every effort should be made to treat other medical conditions prior to beginning gender-affirming treatments. Which of the following would be imperative to address/treat prior to beginning treatments?

Which of the following is true concerning gender-affirming treatments?

For trans men on hormone therapy, labs to assess treatment response should include a complete blood count (CBC). For what, specifically, is it important to monitor the CBC?

Your transgender patient has had a gonadectomy and is no longer on hormone replacement. You should screen for:

Hormonal therapies for trans women carry increased risks for:

For both trans women and trans men receiving gender-affirming treatments, labs should be monitored at regular intervals. The recommendation for follow-up intervals is:

Contraindications for testosterone therapy in trans men include:

Gender-neutral pronouns are often used to avoid assuming the binary gender classifications denoted by pronouns such as he and she. Which of the following is not a gender-neutral pronoun?

While seeing a trans-male patient with an acute complaint, you should not:

The term transgender is used to describe all of the following except:

Assessment and Clinical Decision Making: an Overview

Genomic Assessment: Interpreting Findings and Formulating Differential Diagnosis

Skin

Head, Face, and Neck

The Eye

Ear, Nose, Mouth, and Throat

Cardiac and Peripheral Vascular Systems

Respiratory System

Breasts

Abdomen

Genitourinary System

Male Reproductive System

Female Reproductive System

Musculoskeletal System

Neurological System

Nonspecific Complaints

Psychiatric Mental Health

Pediatric Patients

Pregnant Patients

Older Patients

Persons With Disabilities

Filters

Exam 20: Assessment of the Transgender or Gender Diverse Adult

Which of the following is not a potential side effect/risk with exogenous testosterone therapy?

Among trans women, the risk for deep venous thrombosis is higher if:

Which of the following is true of trans men?

Every effort should be made to treat other medical conditions prior to beginning gender-affirming treatments. Which of the following would be imperative to address/treat prior to beginning treatments?

Which of the following is true concerning gender-affirming treatments?

For trans men on hormone therapy, labs to assess treatment response should include a complete blood count (CBC). For what, specifically, is it important to monitor the CBC?

Your transgender patient has had a gonadectomy and is no longer on hormone replacement. You should screen for:

Hormonal therapies for trans women carry increased risks for:

For both trans women and trans men receiving gender-affirming treatments, labs should be monitored at regular intervals. The recommendation for follow-up intervals is:

Contraindications for testosterone therapy in trans men include:

Gender-neutral pronouns are often used to avoid assuming the binary gender classifications denoted by pronouns such as he and she. Which of the following is not a gender-neutral pronoun?

While seeing a trans-male patient with an acute complaint, you should not:

The term transgender is used to describe all of the following except:

Assessment and Clinical Decision Making: an Overview

Genomic Assessment: Interpreting Findings and Formulating Differential Diagnosis

Skin

Head, Face, and Neck

The Eye

Ear, Nose, Mouth, and Throat

Cardiac and Peripheral Vascular Systems

Respiratory System

Breasts

Abdomen

Genitourinary System

Male Reproductive System

Female Reproductive System

Musculoskeletal System

Neurological System

Nonspecific Complaints

Psychiatric Mental Health

Pediatric Patients

Pregnant Patients

Older Patients

Persons With Disabilities

Filters